Moritz Gerstung leads a research group at EMBL-EBI investigating the underlying mechanisms of cancer development and seeking to understand the differences in therapy success and outcomes in different individuals. His team develops statistical models for relating different layers of genomic, molecular and clinical data to establish connections between genotype and phenotype, and tools to predict outcomes based on comprehensive, high-dimensional datasets. The group also explores the evolutionary dynamics of cancer. He has a PhD in Computational Biology from ETH Zurich (2012), and carried out postdoctoral work at the Wellcome Trust Sanger Institute (2012-2015). Moritz joined EMBL-EBI as a Research group leader in August 2015.
